<DOC>
	<DOCNO>NCT00422435</DOCNO>
	<brief_summary>This study design evaluate performance safety new catheter system .</brief_summary>
	<brief_title>CoStar™ Paclitaxel-Eluting Coronary Stent Catheter System Evaluation</brief_title>
	<detailed_description>This study design evaluate acute Device Success , define attainment &lt; 50 % residual stenosis target lesion .</detailed_description>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Patient ≥18 year age Eligible percutaneous coronary intervention Documented stable unstable angina pectoris ( Canadian Cardiovascular Society Classification 1 , 2 , 3 , 4 ) , document ischemia , document silent ischemia Left ventricular ejection fraction ≥25 % document within last 6 wks Acceptable candidate coronary artery bypass graft surgery A single de novo lesion per study subject may treat study device Each target lesion may compose multiple lesion must completely coverable 1 study stent Cumulative target lesion length per vessel ≤30 mm base visual estimate RVD ≥2.5 mm ≤3.0 mm base visual estimate Target lesion diameter stenosis ≥50 % &lt; 100 % base visual estimate Target vessel undergone prior revascularization within precede 6 month Target lesion must minimum 10 mm distance previously treat segment target vessel Known sensitivity cobalt chromium , paclitaxel polymeric matrix : Translute PLGA Planned treatment PCI device target vessel ( ) MI within 72 hour prior index procedure Patient cardiogenic shock Cerebrovascular Accident within past 6 month Acute chronic renal dysfunction ( creatinine &gt; 2.0 mg/dl &gt; 150 µmol/L ) Contraindication ASA clopidogrel Thrombocytopenia ( platelet count &lt; 100 , 000/mm3 ) Active gastrointestinal bleeding within past three month Any prior true anaphylactic reaction contrast agent Patient currently , treat paclitaxel ( systemic ) within 12 month index procedure Female childbearing potential positive pregnancy test within 7 day index procedure , lactating , intend become pregnant study Life expectancy le 24 month due medical condition Comorbid condition ( ) could limit patient 's ability participate study , compliance followup requirement impact scientific integrity study Currently participate another investigational drug device study complete primary endpoint clinically interfere endpoint study Left main coronary artery disease ( stenosis &gt; 50 % ) , whether protect unprotected Target lesion ostial location ( within 3.0 mm vessel origin ) Target lesion and/or target vessel proximal target lesion severely calcify visual estimation Target lesion involve bifurcation diseased ( &gt; 50 % stenotic ) branch vessel &gt; 2.0 mm diameter require intervention Target lesion totally occluded Thrombolysis In MI ( TIMI flow ≤1 ) Angiographic presence probable definite thrombus Target vessel pretreated unapproved device , directional rotational coronary atherectomy , laser , cut balloon transluminal extraction catheter immediately prior stent placement Prior coronary intervention use brachytherapy segment target vessel The target vessel prior drugeluting stent placement vessel segment ( branch ) proximal intend target lesion site Angiographic restenosis segment target vessel undergone prior percutaneous coronary intervention Angiographic evidence atherosclerotic disease &gt; 50 % diameter stenosis ( visual estimate ) proximal distal target lesion ( applies major epicardial portion target vessel contiguous vessel segment target lesion locate branch vessel ) Prior surgical revascularization target vessel patent graft ( saphenous vein graft arterial conduit ) Target lesion lie within 10 mm prior surgical anastomosis site</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Percutaneous coronary intervention ( PCI )</keyword>
	<keyword>Drug elute stent ( DES )</keyword>
</DOC>